Stages in LAV/HTLV-III lymphadenitis. II. Correlation with clinical and immunological findings. NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Stages in LAV/HTLV-III lymphadenitis. II. Correlation with clinical and immunological findings.

Scand J Immunol. 1987 Jan;25(1):93-9. Unique Identifier : AIDSLINE MED/87120089
Gerstoft J; Pallesen G; Mathiesen L; Dickmeiss E; Lindhardt BO; Hofmann B; Nielsen CM; Petersen CS; Kroon S


Abstract: The aim of the present study was to investigate the relation between the histopathological findings in LAV/HTLV-III lymphadenitis and immunological, clinical, and serological variables. The study group included 38 consecutive homosexual men with persistent generalized lymphadenopathy (PGL) in whom lymph node biopsy was performed. The histopathological lymph node changes were grouped into three stages. Opportunistic infections at the time of biopsy and their development during follow-up were significantly associated with stage III histology (follicular depletion). Analysis of blood from 10 patients with stage III histology revealed significantly (P less than 0.01) decreased proliferative responses of lymphocytes to mitogens and reduced absolute number of CD5+ and CD4+ lymphocytes compared with 17 patients with stage I histology (follicular hyperplasia), whereas patients with stage II histology (follicular involution) had intermediate values. The absolute number of CD8+ lymphocytes was increased in all three stages, as was IgG, while increase in IgM and IgA was restricted to stage III. No difference was observed between the different histopathological stages with respect to the specificity of the anti-LAV/HTLV-III antibody as measured by immunoblotting. In conclusion, the defects of lymphocytes from the blood of LAV/HTLV-III infected persons reflect alterations in secondary lymphoid tissue. Further, there is a close correlation between these alterations and the clinical status of the patients.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/IMMUNOLOGY/*PATHOLOGY Biopsy Homosexuality Human Immunoglobulins/ANALYSIS Lymph Nodes/*PATHOLOGY Lymphadenitis/BLOOD/IMMUNOLOGY/*PATHOLOGY Lymphocyte Transformation Lymphocytes/CLASSIFICATION/IMMUNOLOGY Male Prognosis JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/blood/immunology/KWDpathologybiopsyhomosexualityhumanimmunoglobulins/analysislymphnodes/KWDpathologylymphadenitis/blood/immunology/KWDpathologylymphocytetransformationlymphocytes/classification/immunologymaleprognosisjournalarticle
870530
M8750277


Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .